Taymour Tamaddon has some big shoes to fill.
Last quarter Tamaddon took over the now-$5.8-billion T. Rowe Price Health Sciences Fund [profile] after the resignation of PM Kris Jenner and analysts Mark Bussard and Graham McPhail. Morningstar subsequently downgraded the mutual fund from Gold to Neutral thanks to worries about the change-up. Now the Wall Street Journal's worried, too.
In yesterday's monthly investing in funds Journal Report, Daisy Maxey dives deep into the fund and the PM change, noting that Morningstar isn't the only one expressing concern. S&P Capital IQ downgraded the fun from five stars to four.